Anthony S Marucci bought $308k of CLDX
PRESIDENT & CEO at Celldex Therapeutics, Inc.. 11,500 shares at an average of $26.82, traded Nov 11, 2024, filed Nov 12, 2024.
Score components
- +25RoleCEO
- +14Trade size$308k at market
- +6Relative to holdingsHoldings up 40%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.1%, 3m -18.9%, 6m -27.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-026489, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | POpen-market purchase Common Stock | +11,500 | $26.82 | $308k | 40,284 | Nov 12, 2024 |
Related signals
Other insiders at Celldex Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | CLDXsell Celldex Therapeutics, Inc. | Freddy A. Jimenez SVP & GENERAL COUNSEL | $121k 4,166 shares | -12% | |
| 38Weak | CLDXsell Celldex Therapeutics, Inc. | Richard M. Wright other | $1.2M 49,298 shares | -70% | |
| 15Weak | CLDXsell Celldex Therapeutics, Inc. | Freddy A. Jimenez SVP & GENERAL COUNSEL | $19k 771 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.